Trial · NCT01465997
Adverse events160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 160
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Lacosamide (SS) | 20 | 279 | 40 |
| other | Nasopharyngitis | Infections and infestations | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 16 | 269 | 22 |
| other | Headache | Nervous system disorders | Lacosamide (SS) | 17 | 279 | 28 |
| other | Headache | Nervous system disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 16 | 269 | 26 |
| other | Dizziness | Nervous system disorders | Lacosamide (SS) | 12 | 279 | 13 |
| other | Dizziness | Nervous system disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 17 | 269 | 19 |
| serious | Eosinophilia | Blood and lymphatic system disorders | Lacosamide (SS) | 1 | 279 | 1 |
| serious | Eosinophilia | Blood and lymphatic system disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 0 | 269 | 0 |
| serious | Angina pectoris | Cardiac disorders | Lacosamide (SS) | 2 | 279 | 2 |
| serious | Angina pectoris | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 0 | 269 | 0 |
| serious | Atrial fibrillation | Cardiac disorders | Lacosamide (SS) | 1 | 279 | 1 |
| serious | Atrial fibrillation | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 1 | 269 | 1 |
| serious | Acute myocardial infarction | Cardiac disorders | Lacosamide (SS) | 1 | 279 | 1 |
| serious | Acute myocardial infarction | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 0 | 269 | 0 |
| serious | Cardiac failure | Cardiac disorders | Lacosamide (SS) | 1 | 279 | 1 |
| serious | Cardiac failure | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 0 | 269 | 0 |
| serious | Myocardial ischaemia | Cardiac disorders | Lacosamide (SS) | 1 | 279 | 1 |
| serious | Myocardial ischaemia | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 0 | 269 | 0 |
| serious | Atrioventricular block second degree | Cardiac disorders | Lacosamide (SS) | 0 | 279 | 0 |
| serious | Atrioventricular block second degree | Cardiac disorders | Carbamazepine-Controlled Release (CBZ-CR) (SS) | 1 | 269 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01465997/events